MDAI News & Events

Reports Q4 revenue $3.8M, consensus $2.92M. Q4 EPS included a $4.0M gain in the fair value of the Company's warrant liability. "2025 was a pivotal year for Spectral AI, highlighted by the submission of our De Novo 510 application to the FDA of our DeepView System for burn indication," said Vincent Capone, CEO of Spectral AI. "We continue to make significant progress along numerous fronts in preparation for the anticipated commercialization of this innovative diagnostic device. The reception of our technology at burn conferences in the U.S., UK, and Europe has been exceptional."

FY26 revenue view reflects the continued development of the Company's DeepView System through the BARDA PBS Contract. This guidance does not include any material contributions from the sale of the DeepView System for the burn indication.

Spectral AI announced that it has received $31.7M in funding from the Biomedical Advanced Research and Development Authority, or BARDA, to accelerate and support additional feature aspects for the company's DeepView System, its AI-driven burn wound imaging technology. As part of the ongoing partnership, Spectral AI has committed to provide an additional $9.7M to the total overall development costs associated with these feature advancements. This immediate, non-dilutive funding is being advanced in addition to the $54.9M of funding committed to date as part of the company's current contract with BARDA valued up to $150M, as the company awaits a determination on market authorization from the FDA for the DeepView System.

Spectral AI announced that the Company's Board of Directors has appointed Vincent Capone as Chief Executive Officer of the Company, effective February 9, 2026. The appointment of Capone, who currently serves as the Company's Chief Financial Officer and General Counsel, comes as Spectral AI transitions towards commercialization of its burn wound assessment device - the DeepView System.